Related Experiment Video

Updated: Aug 14, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Treatment algorithm for the management of hepatitis C in HIV-coinfected persons

Mark S Sulkowski1

  • 1Johns Hopkins Medical Institutions, 1830 East Monument Street, Room 319, Baltimore, MD 21287-0003, USA. msulkows@jhmi.edu

Journal of Hepatology
|December 20, 2005
PubMed

Insights

Hepatitis C virus (HCV) treatment in patients with HIV is safe and effective, using peginterferon alfa (PEG-IFN) and ribavirin (RBV). Experts agree on managing HCV in HIV patients, but optimal treatment algorithms require further research.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Hepatitis C virus (HCV) infection significantly contributes to liver disease and mortality in patients with human immunodeficiency virus (HIV).
  • Effective antiretroviral therapy (ART) for HIV has shifted focus to managing comorbidities, including HCV-related liver disease.
  • Expert recommendations include evaluation, treatment consideration, and potential liver transplantation for coinfected individuals.

Purpose of the Study:

  • To review the current evidence on managing HCV-related liver disease in coinfected patients.
  • To assess the safety, tolerability, and efficacy of HCV treatment regimens in HIV-infected individuals.
  • To identify remaining uncertainties in the treatment algorithms for coinfected patients.

Main Methods:

  • Review of randomized controlled trials and expert consensus guidelines.
  • Analysis of safety, tolerability, and efficacy data for peginterferon alfa (PEG-IFN) plus ribavirin (RBV) in HIV-infected populations.
  • Synthesis of current expert recommendations and identification of knowledge gaps.

Main Results:

  • Peginterferon alfa (PEG-IFN) plus ribavirin (RBV) has demonstrated safety, tolerability, and efficacy in treating HCV in HIV-coinfected patients.
  • Despite treatment advancements, managing coinfected patients is complex due to medical, psychiatric, and HIV-related factors.
  • Consensus exists on the necessity of medical management for HCV in HIV-infected individuals.

Conclusions:

  • HCV treatment is feasible and effective in HIV-coinfected patients, supporting expert recommendations for intervention.
  • Further research is needed to establish optimal, individualized treatment algorithms for coinfected patients.
  • Addressing comorbidities and concurrent ART is crucial for successful HCV management in this population.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...